



4 October 2006

MOVIPREP® completes Mutual Recognition Procedure

Norgine, the European specialty pharmaceutical company, is pleased to announce the successful completion of the Mutual Recognition Procedure for its novel bowel preparation, MOVIPREP. The company will now carry out the final work necessary in order to receive national authorisations in the 12 countries covered by this application. The Reference Member State was the UK.

Commenting on this approval Peter Martin, Norgine's Chief Operating Officer stated, "This is another important milestone for Norgine, following the initial approval in the UK. It is the successful culmination of a lot of hard work from people across a wide range of functions within Norgine. We now look forward to the successful launch of MOVIPREP across Europe in the coming months".

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for 100 years and has a presence in all the major European markets. In 2005, Norgine's sales were €171 million, the 19th consecutive year of double-digit growth. The company employs almost 1,000 people, of whom 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL® for the treatment of chronic constipation and faecal impaction, KLEAN-PREP® for bowel preparation prior to colonoscopy, and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

MOVIPREP®, a novel product that Norgine has developed for bowel cleansing prior to colonoscopy, has been granted a marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency, and approved by the US Food and Drug Administration. Norgine has an active Research and Development effort and currently has products at various stages of clinical development. Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk